Related Experiment Video

Updated: Jul 7, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Targeted therapy in renal cell carcinoma

Jean-Jacques Patard1, Damien Pouessel, Karim Bensalah

  • 1Department of Urology, Rennes University Hospital, CHU Pontchaillou, rue Henri le Guillou, 35033 Rennes, France. jean-jacques.patard@univ-rennes1.fr

World Journal of Urology
|February 13, 2008
PubMed
Abstract

Insights

New anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF) improve survival for metastatic renal cell carcinoma patients. Four effective therapies are now available for first and second-line treatment.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Metastatic renal cell carcinoma (mRCC) treatment has advanced with targeted therapies.
  • Understanding molecular pathways in clear cell carcinomas is key to developing new treatments.

Purpose of the Study:

  • To provide an update on anti-angiogenic drugs for metastatic renal cell carcinoma.
  • To summarize current therapeutic options and their efficacy.

Main Methods:

  • Review of clinical trial data for targeted therapies in mRCC.
  • Analysis of drugs targeting vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR).

Main Results:

  • Tyrosine kinase inhibitors targeting VEGF receptors (Sunitinib, Sorafenib) improve progression-free survival.
  • Temsirolimus (mTOR inhibitor) improves overall survival in poor-risk patients.
  • Bevacizumab (anti-VEGF antibody) combined with interferon shows improved response rates and progression-free survival.

Conclusions:

  • Four major anti-angiogenic drugs/regimens are now available for first and second-line mRCC therapy.
  • Further research is needed to optimize drug combinations and evaluate adjuvant therapy effectiveness.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...